dsm-firmenich, the leading innovator in health, nutrition, and beauty, has received a favorable judgement issued by Beijing Intellectual Property Court , which upheld the decision of the China National Intellectual Property Administration (CNIPA) to maintain dsmfirmenich’s Chinese patent relating to swine compound premixes containing 25-hydroxyvitamin D3.
Shandong Haineng Bioengineering Co. Ltd. (herein “Haineng”) has filed an appeal against this judgement.
dsm-firmenich is a pioneer and a world leading manufacturer of 25-hydroxyvitamin D3 – the major circulating form of vitamin D – which is widely used in animal feed under the Hy-D® brand, as well as in other applications.
With this judgement, dsm-firmenich has successfully defended the patent against a second invalidation challenge brought by Haineng before the first instance court. This follows an earlier invalidation challenge by Haineng, which also failed, with the CNIPA decision maintaining the patent in force.
“We are pleased with the consistent recognition of our innovations by the court and CNIPA. It is an example of the strength of our robust patent portfolio in the 25-hydroxyvitamin D3 area. We have a comprehensive patent portfolio around the world, and this protects our continued investments in innovation and our position as a technology leader in 25-hydroxyvitamin D3,” stated Fidelis Fru, head of Business Development Animal Nutrition & Health at dsm-firmenich.
“We look forward to continuing to provide our customers with the highest quality products and services. In the meantime, we proactively monitor third-party activities for potential infringement and acts where necessary to protect against any unauthorized use of our patented technology.”
You can visit their website here.
